MXCDA

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Mgc Pharmaceuticals Ltd

πŸ‡¦πŸ‡Ί ASX

NULL STOCK

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

7
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

MGC Pharmaceuticals Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

πŸ“ˆ Performance

Price History

+3400.00%

1M

10Y

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.42

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in MXCDA

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in MXCDA

N/A
MXCDA investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in MXCDA also invest in...

Argent Biopharma Limited

RGT

Argent Biopharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.

πŸ™Œ Performance (5Yr p.a)

128.57%

πŸ“Š Share price

$0.26 AUD

πŸ“¦ LOGISTICS

Find Out More

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. The company maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. The company has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

πŸ™Œ Performance (5Yr p.a)

220.00%

πŸ“Š Share price

$0.42 AUD

πŸ“¦ LOGISTICS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

12.86%

πŸ“Š Share price

$129.54 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Webjet Ltd. provides online travel booking services. The company is headquartered in Melbourne, Victoria. The principal activity of the Company and its subsidiaries includes the online sale of travel products, including flights and hotel rooms. The firm's business consists of a business-to-business (B2B) wholesale division, which includes WebBeds and two retail business-to-consumer (B2C) businesses, which include Webjet OTA and GoSee. WebBeds is a global marketplace for the travel trade, an intermediary connecting hotels and other travel service suppliers to a distribution network of travel buyers all over the world. Webjet OTA is an online travel agency, which enables customers to compare, combine and book domestic and international travel flight deals, hotel accommodation, holiday package deals, travel insurance and car hire worldwide. GoSee is a global travel e-commerce group, enabling customers to search, compare and book rental cars and motorhomes via two websites, Airport Rentals and Motorhome Republic.

πŸ™Œ Performance (5Yr p.a)

-10.24%

πŸ“Š Share price

$4.10 AUD

🏨 HOTELS, RESTAURANTS & LEISURE

CRYP.AX was created on 2021-11-02 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. CRYP.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to global companies at the forefront of the crypto economy.

πŸ“Š Share price

$5.39 AUD

πŸ€– TECHNOLOGY